Table 1. New Vaccines Containing Serogroup A:

Novel vaccines that are currently in Phase II–III trials that provide MenA coverage. The trials target different age groups and different geographical regions.

New Vaccines Containing Serogroup A
Vaccine Name	Meningococcal Serogroups Covered	Clinical Trial Phase	Targeted Age Group
NmCV-5 (pentavalent meningococcal protein conjugate vaccine, Serum Institute of India Pvt. Ltd.)	A, C, Y, W, X	Phase II: Mali	12-16 months old
		Phase III: Mali and the Gambia	2-10 years old; 11–17 years old; 18–29 years old
		Phase III: India, Africa	2-10 years old; 11–17 years old; 18–29 years old
MenACWY (Oligosaccharide diptheria CRM-197 conjugate, GlaxoSmithKline) combined with meningococcal (group B) multicomponent recombinant (MenABCWY)	A, C, W, Y	Phase IIb: US, Finland, Poland	10-18 years old
MenABCWY (bivalent RLP2086-containing pentavalent vaccine, Pfizer)	A, B, C, W, Y	Phase III: US, Czechia, Finland, Poland	10-26 years old
Tritanrix™-HepB/Hib-MenAC (GlaxoSmithKline)	A, C	Phase III: Thailand	15-24 months old